Imagine a lock and key where the lock keeps changing, making the key useless. This happens when malaria parasites evolve to ignore the drugs we use to kill them. This effort builds a regional warning system to spot these changes early and update the medical 'instruction manual' so doctors use the right medicine. It ensures the current frontline treatments keep working before too many people get sick.
Current first-line malaria treatments are failing due to drug-resistant parasites. This creates a critical need for real-time surveillance and updated treatment guidelines to prevent a spike in deaths.
A regional dashboard, 19 country reports, the MoxieBot chatbot, and a costed Regional Detailed Action Plan.
If you are a drug developer dealing with unpredictable drug efficacy in Africa — this project developed predictive maps and evidence summaries that identify where artemisinin resistance is spreading. This allows you to target new drug launches or adjust formulations for 19 endemic countries.
If you are a software provider dealing with the need for real-time clinical guidance — this project developed the MoxieBot chatbot and MAGICapp summaries. These tools demonstrate how to deliver complex resistance data to primary healthcare workers in a usable digital format.
If you are a consultant dealing with national health planning — this project developed a costed Regional Detailed Action Plan. This provides a blueprint for implementing resistance surveillance across 19 countries.
Based on available project data, the specific costs are not listed, although the project is co-designing a 'costed' Regional Detailed Action Plan.
The project aims to provide an evidence-based, reproducible model for mitigating drug resistance, which suggests it can be adapted for other malaria-endemic regions.
Based on available project data, the toolkit and dashboard are described as 'freely available', suggesting an open-access rather than a proprietary licensing model.
The project translates evidence into policy to inform malaria treatment guidelines in at least eight countries to prevent treatment failure.
The project period runs from 2023-04-01 to 2027-03-31.
The consortium is heavily research-oriented, consisting of 6 universities and 2 research institutes. However, it maintains a strategic footprint across 9 countries, including key hubs in Africa (ZA, RW, UG) and Europe (DE, NL, NO, SE, UK). With 1 industry partner and 2 SMEs, the group is designed for knowledge transfer and policy influence rather than mass commercial production, focusing on the translation of clinical data into national health guidelines.
Contact the University of Cape Town regarding the Regional Detailed Action Plan.
Contact us to explore how to integrate these resistance maps into your pharmaceutical market strategy.
